Several recent preclinical studies have demonstrated that AMG 330 is highly potent in causing cytolysis of CD33+ AML cell lines or primary human AML cells in the presence of healthy donor T-cells or autologous T-cells from AML patients at low effector-to-target (E:T) cell ratio [14–17]. Here, CD33 is linked to acute myeloid leukemia.